Mednow Inc (TSX-V:MNOW, OTCQB:MDNWF) said it has signed a two-year investment agreement to acquire the license and exclusive distribution rights of TruDiagnostic in Canada.
Under the agreement, Mednow said it paid a one-time licensing fee of US$150,000 to TruDiagnostic for access and use of the TruDiagnostic Technology and TruDiagnostic Platform for the development, importation, use, marketing, sale, and distribution of the Epigenetic Testing Kits.
Mednow said its strategy is to develop a digital interdisciplinary model of care, anchored in pharmacy and supported by telemedicine and complementary health care services. Having the exclusive distribution rights of TruDiagnostic in Canada will enhance Mednow’s approach to provide a full spectrum health care ecosystem, as the company intends to continue to build a holistic approach to patient care.
READ: Mednow closes acquisition of pharmacy in British Columbia
TruDiagnostic’s TruAge Complete Collection is a comprehensive way for a patient to analyze methylation biomarkers to quantify the process of aging, allowing individuals to potentially predict future diseases and treat aging as a primary objective factor.
The TruAge Complete collection allows everyone to look at their aging process by providing them their biological age, immune age, and telomere length. It also includes the Dunedin Pace of Aging analysis, developed by Duke University.
Mednow noted that the Dunedin Pace of Aging analysis is the only publicly available aging algorithm trained on phenotypes and variables of health, rather than chronological age. It also offers analysis and reporting for other health and age-related biomarkers such as the ability to lose weight with caloric restriction, immune cell subsets, and more.
In the first quarter of 2022, Mednow said it anticipates that its patients will be able to order the test on its website, have their blood specimen taken and shipped back to the lab for testing and diagnosis.
“We continually endeavor unique pharmacy and healthcare solutions as part of our patient-centric approach,” said Mednow CEO Karim Nassar in a statement.
“We recognize Canadians are expanding their initiatives when it comes to preventative medicine. By acquiring the exclusive distribution rights to TruDiagnostic we can deliver a solution for epigenetic testing for patients to live their healthiest life.”
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham